Healthcare: CCA extends work for Equasym XL

UCB Pharma is using Chandler Chicco Agency for UK medical education work around its attention deficit hyperactivity disorder (ADHD) product Equasym XL.

The contract cements the agency's grip on the brand, which it helped to launch last year. Priority targets are child and adolescent psychiatrists and paediatricians.

According to the National Institute for Clinical Excellence, around one per cent of school children have severe ADHD.

The brand was previously produced by biotech firm Celltech, which was taken over by UCB last summer.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in